41 results about "Circulating miRNA" patented technology

The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other bood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated isidentified, evaluated or classified according to the method of the invention.

The invention provides circulating miRNAs (namely microRNAs) for early diagnosis of acute coronary syndromes and an application thereof. The circulating miRNAs comprise miR-3149 and / or miR-122, further comprise miR-2861, and further comprise miR-140-3p and / or miR-720. The circulating miRNAs provided by the invention can be taken as markers to be applied to early diagnosis of the acute coronary syndromes.

The invention relates to the field of biomedicine, in particular to a real-time fluorescent quantitative RT-qPCR method for directly detecting circulating microRNA (miRNA) in serum or plasma without extracting nucleic acid. The method includes: S1: lysing exosomes and miRNA protein complexes in serum or plasma, and centrifuging to obtain crude circulating miRNA extracts; S2: miRNA tailing and reverse transcription; S3: RT-qPCR quantitative detection. In the miRNA direct fluorescent quantitative RT-qPCR amplification method [Direct S-Poly(T) Plus, DSPP for short] of the present invention, nucleic acid does not need to be extracted, and the Poly(A) tailing and reverse transcription of miRNA will be in one reaction system Synchronously completed, easy to operate and shorten the time, the preparation of cDNA can be completed within 95 minutes. Compared with the stem-loop method, the sensitivity of this technical system is increased by tens or even hundreds of times, and a very simple, sensitive, efficient, fast and cheap miRNA detection technical system has been established. This technical system is especially suitable for clinical application promotion and detection of miRNA from biological fluid samples with low miRNA abundance.

The invention discloses a circulating miRNA marker related to the auxiliary diagnosis of endometrial cancer and its application. The marker is a plasma marker miR-142-3p, miR-146a-5p and miR-151a-5p and a serum marker One or more of miR-143-3p, miR-195-5p, miR-20b-5p, miR-204-5p, miR-423-3p and miR-484. As a new type of biomarker, circulating miRNA has the characteristics of good stability, minimally invasive and easy access, high sensitivity and specificity. The development and utilization of such molecular markers will provide a new direction for the diagnosis and further treatment of various diseases including tumors. This study will be more targeted to obtain circulating miRNA markers with clinical diagnostic potential in endometrial cancer. The study confirmed the reliability and reproducibility of this group of miRNAs as non-invasive markers for the diagnosis of endometrial cancer.

The invention relates to circulating miRNA-4731-3p as a diagnostic marker for primary lung cancer and a detection method thereof. Through high-throughput screening of circulating miRNAs in the plasma of patients diagnosed with lung cancer, and comparing them with the corresponding miRNAs in the plasma of healthy subjects, we found the highly expressed MiRNA‑4731‑3p as the target of this experiment Mark. The expression level of miRNA‑4731‑3p was significantly higher than that of the control group P<0.001. ROC curve analysis showed that the efficacy of miRNA‑4731‑3p in distinguishing normal people from lung cancer patients was AUC=0.048, the sensitivity was 95.0%, and the specificity was 57.5%. Survival curve analysis showed that the higher the expression level, the shorter the survival period, on the contrary, the lower the expression level, the longer the survival period.